Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators

Abstract

Background: In the scope of the European Commission Initiative on Breast Cancer (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with breast cancer (BC) mortality. This paper documents the methodology used for the indicator selection. Methods: The indicators were identified through a multi-stage process. First, a scoping review was conducted to identify existing performance indicators. Second, building on existing frameworks for making well-informed health care choices, a specific conceptual framework was developed to guide the indicator selection. Third, two group exercises including a rating and ranking survey were conducted for indicator selection using predetermined criteria, such as: relevance, measurability, accurateness, ethics and understandability. The selected indicators were mapped onto a BC screening pathway developed by the M&E subgroup to illustrate the steps of BC screening common to all EU countries. Results: A total of 96 indicators were identified from an initial list of 1325 indicators. After removing redundant and irrelevant indicators and adding those missing, 39 candidate indicators underwent the rating and ranking exercise. Based on the results, the M&E subgroup selected 13 indicators: screening coverage, participation rate, recall rate, breast cancer detection rate, invasive breast cancer detection rate, cancers > 20 mm, cancers ≤10 mm, lymph node status, interval cancer rate, episode sensitivity, time interval between screening and first treatment, benign open surgical biopsy rate, and mastectomy rate.

A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer

“…Therefore, the efficiency of our strategy cannot be confirmed yet, but need to be monitored carefully once implemented and can continuously be adapted to new insights gained by experience and long-term data, which will become available in the future. Monitoring and evaluation after implementation can be done according to the procedure as described, for example, breast cancer screening [66] in the European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis [67,68]. Up to now, the benefits of RCs and MRI within the detection of PCa have been proved only from clinical cohorts.…”

Impact of the COVID-19 pandemic on breast cancer screening indicators in a Spanish population-based program: a cohort study

“…The programs follow the guidelines of the European Commission Initiative for Breast Cancer Screening and Diagnosis ( The European Commission’s science and knowledge service, 2020 ). These guidelines recommend an evidence-based set of performance indicators to evaluate the quality of the screening provision ( Muratov et al, 2020 ). The suspension of these programs led to a reduction in cancer diagnoses.…”

Impact of the COVID-19 pandemic on breast cancer screening indicators in a Spanish population-based program: a cohort study

“…The programs follow the guidelines of the European Commission Initiative for Breast Cancer Screening and Diagnosis (4). These guidelines recommend an evidence-based set of performance indicators to evaluate the quality of the screening provision (5). The suspension of these programs led to a reduction in cancer diagnoses.…”